AR095962A1 - Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos - Google Patents
Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentosInfo
- Publication number
- AR095962A1 AR095962A1 ARP140101440A ARP140101440A AR095962A1 AR 095962 A1 AR095962 A1 AR 095962A1 AR P140101440 A ARP140101440 A AR P140101440A AR P140101440 A ARP140101440 A AR P140101440A AR 095962 A1 AR095962 A1 AR 095962A1
- Authority
- AR
- Argentina
- Prior art keywords
- sterol
- nanoparticles
- amphipathic
- carriers
- molecules
- Prior art date
Links
- 229930182558 Sterol Natural products 0.000 title abstract 5
- 239000002105 nanoparticle Substances 0.000 title abstract 5
- 235000003702 sterols Nutrition 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 150000003432 sterols Chemical class 0.000 title abstract 4
- 241001092142 Molina Species 0.000 title abstract 2
- 241001454523 Quillaja saponaria Species 0.000 title abstract 2
- 235000009001 Quillaja saponaria Nutrition 0.000 title abstract 2
- 239000000969 carrier Substances 0.000 title abstract 2
- 238000013329 compounding Methods 0.000 title 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical class CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 title 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003172 aldehyde group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 150000003505 terpenes Chemical class 0.000 abstract 1
- 235000007586 terpenes Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una nanopartícula que comprende al menos un esterol, ej. colesterol y un componente de Quillaja Saponaria Molina (QuilQ) seleccionado de la saponina de quillaja, caracterizado porque dichas nanopartículas no comprenden un fosfolípido y porque la molécula de esterol está unida por un enlace hidrofóbico entre el grupo hidroxilo del esterol y las fracciones terpeno en una micela de Quil A y mediante un enlace de éster hidrofílico entre un OH⁻ de esterol y COOH⁻ o grupos aldehídos en la micela de Quil A. Asimismo, se refiere a una composición que comprende las nanopartículas y el uso de las mismas como adyuvante, especialmente en vacunas, como portadores de moléculas anfipáticas e hidrofóbicas y como agentes e tratamiento del cáncer. Además, se refiere a un método para producir las nanopartículas libres de fosfolípidos, un método para el tratamiento del cáncer y un método para evaluar la aplicabilidad del método para tratar el cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350405 | 2013-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095962A1 true AR095962A1 (es) | 2015-11-25 |
Family
ID=50639888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101440A AR095962A1 (es) | 2013-04-01 | 2014-03-31 | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US9907846B2 (es) |
| AR (1) | AR095962A1 (es) |
| WO (1) | WO2014163558A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3311827T3 (da) | 2011-10-03 | 2023-04-03 | Canqura Oncology Ab | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9907846B2 (en) * | 2013-04-01 | 2018-03-06 | Mx Adjuvac Ab | Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11510859B2 (en) | 2015-07-16 | 2022-11-29 | Marinomed Biotech Ag | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
| EP3324933B1 (en) * | 2015-07-16 | 2020-12-16 | Marinomed Biotech AG | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US20190098895A1 (en) * | 2016-03-09 | 2019-04-04 | Technion Research And Development Foundation Ltd. | Liposomal formulations and methods of using same in agriculture |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| CA3027885A1 (en) * | 2016-06-15 | 2017-12-21 | Ojai Energetics Pbc | Methods and compositions for potentiating stem cell therapies |
| EA201990030A1 (ru) * | 2016-06-15 | 2019-06-28 | ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи | Способы и композиции для снижения окислительного стресса |
| WO2018075830A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| CN108686226B (zh) * | 2018-07-03 | 2020-05-22 | 上海交通大学 | 以碱基为载体的纳米药物输送体系 |
| CN110680819A (zh) * | 2018-07-06 | 2020-01-14 | 云南民族大学 | 一种三萜皂苷类化合物的应用 |
| US11547672B2 (en) * | 2018-09-14 | 2023-01-10 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
| EP3669890A1 (en) | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
| EP3897739B1 (en) | 2018-12-21 | 2024-04-17 | Sapreme Technologies B.V. | Saponin conjugates |
| FR3110427B1 (fr) * | 2020-05-20 | 2023-07-14 | Laboratoires Eriger | Conjugué terpenique de couplage |
| WO2024107474A1 (en) * | 2022-11-15 | 2024-05-23 | Massachusetts Institute Of Technology | Controlled lipid self-assembly for scalable manufacturing of next-generation immune stimulating complexes |
| SE2200142A1 (en) * | 2022-12-13 | 2024-06-14 | Savacc Ab | Chrisvacc |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US3046301A (en) | 1959-10-29 | 1962-07-24 | Burroughs Wellcome Co | Method of making chlorambucil |
| US3803124A (en) | 1968-04-12 | 1974-04-09 | Farmaceutici It Soc | Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives |
| GB1235022A (en) | 1969-06-04 | 1971-06-09 | Laeaeke Ag | A new method for the production of cyclophosphamide |
| DE2124023C3 (de) | 1970-05-27 | 1980-07-10 | Richter Gedeon Vegyeszeti Gyar R.T., Budapest | Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten |
| US4020270A (en) | 1974-05-02 | 1977-04-26 | Societa' Farmaceutici Italia S.P.A. | L-lyxohex-1-enopyranose derivative |
| GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
| US4307100A (en) | 1978-08-24 | 1981-12-22 | Agence Nationale De Valorisation De La Recherche (Anvar) | Nor bis-indole compounds usable as medicaments |
| DE2845574A1 (de) | 1978-10-19 | 1980-04-24 | Deutsches Krebsforsch | Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| EP0111058B1 (en) | 1982-11-26 | 1987-11-04 | Nippon Kayaku Kabushiki Kaisha | Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| GB8919819D0 (en) | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| IT1250692B (it) | 1991-07-23 | 1995-04-21 | Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi. | |
| US5476932A (en) | 1994-08-26 | 1995-12-19 | Hoffmann-La Roche Inc. | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
| GB9719426D0 (en) | 1997-09-13 | 1997-11-12 | Johnson Matthey Plc | Novel process |
| JP2004528321A (ja) | 2001-04-04 | 2004-09-16 | ノルディック ワクチン テクノロジー アクティーゼルスカブ | ステロールおよびサポニンを含むポリヌクレオチド結合複合体 |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| WO2004030696A2 (en) | 2002-10-02 | 2004-04-15 | Nordic Vaccine Technology A/S | Composition for vaccination |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| US9498457B2 (en) * | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| DE102006007903A1 (de) | 2005-12-21 | 2007-07-05 | VD-Werkstätten GmbH & Co KG | Verfahren für die Herstellung von Möbel-Formteilen |
| US20080063129A1 (en) * | 2006-09-11 | 2008-03-13 | Nokia Corporation | System and method for pre-defined wake-up of high speed serial link |
| AU2007322424B2 (en) | 2006-11-20 | 2013-05-16 | Duecom | Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| CN102470168A (zh) | 2009-07-10 | 2012-05-23 | 伊斯克诺瓦公司 | 新组合物 |
| DK3311827T3 (da) | 2011-10-03 | 2023-04-03 | Canqura Oncology Ab | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser |
| US9907846B2 (en) * | 2013-04-01 | 2018-03-06 | Mx Adjuvac Ab | Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions |
-
2014
- 2014-03-31 US US14/781,761 patent/US9907846B2/en active Active
- 2014-03-31 AR ARP140101440A patent/AR095962A1/es not_active Application Discontinuation
- 2014-03-31 WO PCT/SE2014/050380 patent/WO2014163558A1/en not_active Ceased
-
2017
- 2017-12-15 US US15/844,152 patent/US20180104330A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9907846B2 (en) | 2018-03-06 |
| US20160045595A1 (en) | 2016-02-18 |
| WO2014163558A1 (en) | 2014-10-09 |
| US20180104330A1 (en) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095962A1 (es) | Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos | |
| IN2014DN03485A (es) | ||
| BR112015022819A8 (pt) | método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal | |
| CO2022001097A2 (es) | Formulaciones anti-c5 de alta concentración | |
| BR112022019124A2 (pt) | Composições e métodos para liberação de rna | |
| CO6501190A2 (es) | Vacuna de pcsk9 | |
| MX386182B (es) | Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos. | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| MX2023006541A (es) | Formulaciones de dosis fija. | |
| PE20170904A1 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| CO2017007959A2 (es) | Composiciones farmacéuticas para terapia combinada | |
| BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
| MX2016007658A (es) | Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl. | |
| CL2019002362A1 (es) | Formulaciones de evolocumab de baja viscosidad y alta concentración y métodos de elaboración de las mismas. | |
| JP2016502551A5 (es) | ||
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| MX377089B (es) | Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral. | |
| AR061622A1 (es) | Esteres del acido docosahexaenoico(dha), en particular el docosahexaenoato de piridin-3-il-metilo, metodo de preparacion, composicion farmaceutica que los contiene y su utilizacion en el tratamiento y prevencion de enfermedades cardiovasculares | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| WO2014152451A3 (en) | Compositions and methods for controlled localized delivery of bone forming therapeutic agents | |
| BR112022025105A2 (pt) | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| AR117712A1 (es) | Nanopartículas filamentosas que tienen efecto adyuvante de vacuna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |